Jonathan Bryan

Jonathan Bryan serves as a key procurement lead within the National Institute of Allergy and Infectious Diseases (NIAID), supporting the agency’s mission to accelerate biomedical research against infectious, immunologic, and allergic diseases. He manages a portfolio of research and development contracts focused on advancing medical countermeasures, diagnostic platforms, and high-containment laboratory infrastructure. His acquisitions primarily support preclinical and translational research, with emphasis on biosafety-compliant technologies and biological product development. Bryan’s work ensures timely procurement of specialized scientific services and equipment critical to national public health preparedness. His primary contractor relationships center on Quality Biological, Inc., a leading provider of biological reference materials and biosafety-critical reagents, and Genomic Labs Ltd., a specialist in genomic sequencing and infectious disease diagnostics. These partnerships reflect a strategic focus on high-integrity, regulated suppliers capable of supporting BSL-3/4 research environments. Bryan maintains consistent, long-term vendor engagements with firms possessing validated GMP and GLP capabilities, prioritizing technical reliability and regulatory compliance over volume-based sourcing. Bryan’s contracting approach reflects a balanced commitment to socioeconomic goals, with 25% of awards designated as total small business set-asides under FAR 19.5, while the majority of acquisitions remain open to all competitors. This pattern underscores a deliberate effort to foster innovation from small businesses without compromising the technical rigor required for high-consequence research. His procurement strategy actively encourages participation from small businesses with niche expertise in biologics manufacturing and diagnostic development. His primary NAICS focus is 541714—Research and Development in Biotechnology—reflecting deep expertise in procuring advanced biotech R&D services, including recombinant protein production, viral vector development, and immunological assay validation. He also routinely acquires biological product manufacturing (325414) and analytical laboratory instrumentation (334516), demonstrating domain-specific knowledge in biosafety-compliant technologies and high-sensitivity diagnostic systems essential to NIAID’s response infrastructure.